Loading organizations...
§ Private Profile · Apartment 2, 4-6 St Edmund's Terrace, London, NW8 7ET
Biotechnology company developing an AI platform for genetic optimization of microorganism strains in precision fermentation.
Based in London, UK, Eden Bio develops a machine learning platform that genetically optimizes microorganism strains to increase protein yields in precision fermentation. The company provides AI-driven strain engineering services to biotechnology businesses, addressing complex scale-up challenges and improving enzymatic activity for sustainable commercial protein production. Operating from laboratory facilities in White City with a team of eight employees, the enterprise plans to generate revenue by taking royalties from scaled-up manufacturing. The organization raised £1 million in seed funding in November 2022 through a financing round led by SynBioVen, alongside investments from Dhyan Capital and Saras Capital. Following this investment, the firm initiated a seed extension funding round targeting completion by July 2024 to further develop its proprietary technology. Eden Bio was founded in 2022 by Dr Christopher Reynolds, Dr Rachel Shaw, and Dr Evgenia Markova.
Eden Bio has raised $1.0M across 1 funding round.
Eden Bio has raised $1.0M in total across 1 funding round.
Eden Bio has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in November 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2022 | $1M Seed | Synbioven | 7percent Ventures, Dragonfly Capital, Hack VC, Meta Change Capital, #secretfund, Unruly Capital, Spencer Noon, XAnge, Didier Valet, Ernest Oppetit, Fernando Martinelli, Frederic Montagnon, Itamar Lesuisse, John Lilic, Julien Romanetto, Nicolas Debock, Nicolas Steegmann, Andy Russell, Kevin Mascarenhas, Noor Shaker, Stefano Bernardi, Dhyan Capital, Saras Capital | Announced |
Eden Bio is a UK-based biotechnology company specializing in strain engineering for fermentation-based industries, using a proprietary machine-learning platform to optimize microorganisms for higher protein yields in precision fermentation.[3][4][5] Founded in 2021, it serves clients in food, pharmaceuticals, and biofuels by fine-tuning genetic modifications to boost yield and enzymatic activity, addressing the need for sustainable alternatives to traditional farming and manufacturing.[3][5] The company supports the biomanufacturing revolution by enabling other firms to produce proteins more efficiently, with a team integrating wet-lab synthetic biology and dry-lab machine learning expertise.[4]
As of late 2025, Eden Bio Ltd (company number 13670126) is in liquidation, with its last accounts filed to October 31, 2024, and an overdue confirmation statement.[6] Despite early promise—including plans for a seed extension funding round in 2024—it has ceased active operations, marking a pivot or closure in its growth trajectory.[4][6]
Eden Bio was incorporated on October 8, 2021, in the UK, with its registered office in Milton Keynes, Buckinghamshire.[6] It was co-founded by Dr. Rachel Shaw (CEO, former Research Information Manager at Cancer Research UK), Dr. Christopher Reynolds (CTO, prior co-founder of Better Dairy, which pioneered precision fermentation for alternative dairy), and Dr. Evgenia Markova (CSO, former founder at Entrepreneur First).[4] The idea emerged from Reynolds' expertise in machine learning and synthetic biology, recognizing the need to apply these tools across biotech verticals beyond dairy to optimize microbial strains for protein production.[4]
Early traction built on this foundation, with the company launching in January 2022 and growing to a team of eight by 2024, blending wet and dry lab capabilities.[4] It positioned itself as a partner for fermentation businesses transitioning to sustainability, but by 2025, it entered liquidation, halting further development.[3][4][6]
(Note: These strengths were highlighted pre-liquidation; current status limits ongoing differentiation.[6])
Eden Bio rode the biomanufacturing boom fueled by AI integration and high-throughput genetic engineering, aligning with the global push for sustainable alternatives to petrochemicals and traditional agriculture.[4][5] Its timing capitalized on precision fermentation's rise—post-2020 advancements in ML for biotech—making it relevant amid climate-driven demands for biofuels, alt-proteins, and pharma intermediates.[3][4]
Market forces like regulatory support for green biotech (e.g., EU organic approvals in related fields) and investor interest in AI-bio hybrids favored it, influencing the ecosystem by lowering barriers for fermentation adopters.[2][4] Though now in liquidation, it exemplified how specialized strain services accelerate industry transitions, potentially inspiring similar AI-strain engineering ventures.[6]
Eden Bio's liquidation signals challenges in scaling AI-biotech startups amid funding constraints and execution risks in precision fermentation.[6] What's next appears limited: asset sales or team dispersal could seed new ventures, with founders' track record (e.g., Better Dairy) likely fueling reboots elsewhere.[4]
Shaping trends include AI's deepening role in synbio and fermentation economics improving via cheaper compute/genomics; Eden Bio's model may evolve through acquirers targeting its IP for sustainable protein production.[4][5] Its brief arc underscores biotech's high-stakes nature—early innovation meets market hurdles—tying back to its origins as a sustainability pioneer now navigating closure.
Eden Bio has raised $1.0M in total across 1 funding round.
Eden Bio's investors include SynBioVen, 7percent Ventures, Dragonfly Capital Partners, Hack VC, Meta Change Capital, #SecretFund, Unruly Capital, Spencer Noon, XAnge, Didier Valet, Ernest Oppetit, Fernando Martinelli.